GLP-1 Nuclear Localization via UTMD for Myocardial Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac-related medical conditions, such as congestive heart failure and cardiomyopathy, lack effective methods for cardiac muscle regeneration and reversal of heart failure, particularly in cases induced by chemotherapy drugs like Adriamycin.
Innovation Solution
The use of ultrasound-targeted microbubble destruction (UTMD) to deliver GLP-1 polynucleotides or peptides directly to the heart, allowing for nuclear localization and stimulation of cardiac muscle cell proliferation, differentiation, and transdifferentiation, thereby promoting myocardial regeneration and reversing cardiomyopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 is delivered to cardiomyocytes, then cardioprotective effects are achieved, but GLP-1 cannot enter the nucleus without specific delivery mechanisms
Solution Approach 1:
The patent uses cell-penetrating peptides (CPPs) as intermediary carriers to transport GLP-1 across the cell membrane and into the nucleus. The CPPs act as mediators that enable GLP-1 entry into cardiomyocytes and nuclear transport without requiring complex viral vectors or transfection systems, thereby achieving reliable cardioprotective effects while maintaining relatively simple delivery mechanisms.
2Reliability
If traditional GLP-1 signaling pathways are used, then indirect cardioprotection is achieved, but direct nuclear localization and regenerative effects are not realized
Solution Approach 1:
The patent employs preliminary action by pre-fusing GLP-1 with cell-penetrating peptides and nuclear localization signals before administration. This pre-preparation ensures that upon reaching the target tissue, GLP-1 can immediately penetrate the cell membrane and enter the nucleus without requiring additional complex delivery steps, thereby simultaneously achieving reliable cardioprotection and promoting myocardial regeneration through direct nuclear action.
3Reliability
If high doses of GLP-1 are administered, then therapeutic effects are enhanced, but off-target effects and metabolic interference increase
Solution Approach 1:
The patent applies local quality by using cell-penetrating peptides and nuclear localization signals to ensure that GLP-1 is delivered specifically to cardiomyocyte nuclei rather than distributing systemically. This targeted delivery concentrates the therapeutic effect locally in the heart tissue where it is needed, enhancing therapeutic efficacy while minimizing off-target effects and metabolic interference that would occur with high-dose systemic administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to significant overexpression of GLP-1 in cardiac cells, resulting in myocardial regeneration and reversal of established cardiomyopathy, even in cases induced by Adriamycin, with potential applications in treating various cardiac-related conditions.
Implementation Method 1
The use of ultrasound-targeted microbubble destruction (UTMD) to deliver GLP-1 polynucleotides or peptides directly to the heart
Implementation Method 2
ultrasound-targeted microbubble destruction (UTMD)
Implementation Method 3
allowing for nuclear localization and stimulation of cardiac muscle cell proliferation, differentiation, and transdifferentiation
Data Source
AI summary
Embodiments of the disclosure provide methods and/or compositions useful for an individual in need of treatment of a cardiac-related medical condition. In particular cases, GLP-1 is employed in a ultrasound targeted microbubble destruction (UTMD) system for delivery to cardiac tissue, thereby stimulating myocardial regeneration and, in at least some cases, reversal of cardiomyopathy.